Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
30.00
+0.31 (1.04%)
May 28, 2026, 8:34 AM EDT - Market open

Sutro Biopharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-153.6-191.09-227.46-106.79-119.2-105.54
Depreciation & Amortization
6.77.327.226.825.694.84
Stock-Based Compensation
10.0314.0124.6924.9126.323.24
Other Adjustments
41.7642.92-4.88-2.17-13.6513.39
Change in Receivables
1.084.6427.46-28.965.34-6.9
Changes in Accounts Payable
-3.13-2.470.714.81-1.232.71
Changes in Accrued Expenses
0.25.29-9.1426.848.298.46
Changes in Unearned Revenue
-66.91-69.737.85-32.693.65-15.21
Changes in Other Operating Activities
10.5711.87-17.98-4.48-1.65-6.69
Operating Cash Flow
-151.61-177.23-191.54-111.623.55-81.68
Capital Expenditures
-0.53-1.7-3.1-4.32-7.86-15.32
Purchases of Investments
-247.27-264.95-461.52-460.3-216.67-248.73
Proceeds from Sale of Investments
263.81311.66683.13460.69189.5166.73
Other Investing Activities
----0.010.01
Investing Cash Flow
-2.745.01218.51-3.92-35.02-97.32
Long-Term Debt Repaid
---4.08-12.5-9.38-
Net Long-Term Debt Issued (Repaid)
---4.08-12.5-9.38-
Issuance of Common Stock
103.370.3898.6514.3458.154.25
Repurchase of Common Stock
-0.31-0.33-0.51-0.49-0.46-0.99
Net Common Stock Issued (Repurchased)
103.050.0498.1413.8557.693.26
Other Financing Activities
---136.21--
Financing Cash Flow
103.050.0494.05137.5548.313.26
Net Cash Flow
-32.55-132.17121.0222.0116.84-175.74
Free Cash Flow
-152.14-178.93-194.64-115.93-4.31-97
FCF Margin
-152.74%-174.59%-313.72%-75.41%-6.36%-156.76%
Free Cash Flow Per Share
-15.70-21.06-25.16-19.27-0.85-21.03
Levered Free Cash Flow
-206.71-240.5-245.99-122.21-31.68-126.74
Unlevered Free Cash Flow
-172.52-207.7-255.4-110.53-34.81-119.73
Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q